全文获取类型
收费全文 | 5999篇 |
免费 | 329篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 99篇 |
儿科学 | 84篇 |
妇产科学 | 92篇 |
基础医学 | 623篇 |
口腔科学 | 198篇 |
临床医学 | 569篇 |
内科学 | 1669篇 |
皮肤病学 | 57篇 |
神经病学 | 726篇 |
特种医学 | 291篇 |
外科学 | 944篇 |
综合类 | 6篇 |
预防医学 | 211篇 |
眼科学 | 55篇 |
药学 | 308篇 |
中国医学 | 9篇 |
肿瘤学 | 467篇 |
出版年
2024年 | 13篇 |
2023年 | 104篇 |
2022年 | 185篇 |
2021年 | 297篇 |
2020年 | 218篇 |
2019年 | 234篇 |
2018年 | 251篇 |
2017年 | 157篇 |
2016年 | 234篇 |
2015年 | 237篇 |
2014年 | 289篇 |
2013年 | 368篇 |
2012年 | 529篇 |
2011年 | 502篇 |
2010年 | 270篇 |
2009年 | 243篇 |
2008年 | 310篇 |
2007年 | 336篇 |
2006年 | 282篇 |
2005年 | 256篇 |
2004年 | 247篇 |
2003年 | 229篇 |
2002年 | 166篇 |
2001年 | 50篇 |
2000年 | 36篇 |
1999年 | 45篇 |
1998年 | 40篇 |
1997年 | 34篇 |
1996年 | 24篇 |
1995年 | 23篇 |
1994年 | 17篇 |
1993年 | 19篇 |
1992年 | 22篇 |
1991年 | 20篇 |
1990年 | 18篇 |
1989年 | 14篇 |
1988年 | 6篇 |
1987年 | 12篇 |
1986年 | 12篇 |
1985年 | 10篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 7篇 |
1981年 | 3篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1973年 | 4篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1957年 | 2篇 |
排序方式: 共有6408条查询结果,搜索用时 15 毫秒
101.
The turbinal flap: an additional option for anterior skull base reconstruction. Cadaveric feasibility study and case report 下载免费PDF全文
102.
103.
Bertini M Ziacchi M Biffi M Martignani C Saporito D Valzania C Diemberger I Cervi E Frisoni J Sangiorgi D Branzi A Boriani G 《The American journal of cardiology》2008,102(10):1373-1377
Present devices for cardiac resynchronization therapy offer the possibility of tailoring the hemodynamic effect of biventricular pacing by optimization of the interventricular delay (VV) beyond atrioventricular (AV)-interval optimization. It was not yet defined whether a QRS width-based strategy may be a helpful tool for echocardiography for device programming. The aim of the study was to investigate the relation between VV-interval optimization guided by echocardiography and guided by QRS interval width. One hundred six patients with a cardiac resynchronization therapy device for > or =3 months were enrolled. All patients underwent echocardiographic AV and VV delay optimization. The AV interval was optimized according to the E wave-A wave (EA) interval and left ventricular filling time. At the optimal AV delay, VV optimization was performed by measuring the aortic velocity time integral at 5 different settings: simultaneous right and left ventricle output, left ventricle pre-excitation (left ventricle + 40 and 80 ms, respectively), and right ventricle pre-excitation (right ventricle + 40 and 80 ms, respectively). A 12-lead electrocardiogram was recorded and QRS duration was measured in the lead with the greatest QRS width. The electrocardiographic (ECG)-optimized VV interval was defined according to the narrowest achievable QRS interval among 5 VV intervals. The echocardiographic-optimized VV interval was left ventricle + 40 ms in 28 patients, left ventricle + 80 ms in 15 patients, simultaneous in 46 patients, right ventricle + 40 ms in 14 patients, and right ventricle + 80 ms in 3 patients. Significant concordance (kappa = 0.69, p <0.001) was found between the echocardiographic- and ECG-optimized VV interval. In conclusion, significant concordance appeared to exist during biventricular pacing between VV programming based on the shortest QRS interval at 12-lead ECG pacing and echocardiographic-guided VV-interval optimization. A combined ECG- and echocardiographic approach could be a less time-consuming solution in performing this operation. 相似文献
104.
Charles L Bennett Benjamin Kim Anaadriana Zakarija Nicholas Bandarenko Dilip K Pandey Charlie G Buffie June M McKoy Amul D Tevar John F Cursio Paul R Yarnold Hau C Kwaan Davide De Masi Ravindra Sarode Thomas J Raife Joseph E Kiss Dennis W Raisch Charles Davidson J Evan Sadler Thomas L Ortel X Long Zheng Seiji Kato Masanori Matsumoto Masahito Uemura Yoshihiro Fujimura 《Journal of the American College of Cardiology》2007,50(12):1138-1143
OBJECTIVES: We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP). BACKGROUND: The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 most common drugs associated with TTP in databases maintained by the U.S. Food and Drug Administration (FDA). METHODS: Clinical reports of TTP associated with clopidogrel and ticlopidine were identified from medical records, published case reports, and FDA case reports (n = 128). Duration of thienopyridine exposure, clinical and laboratory findings, and survival were recorded. ADAMTS13 activity (n = 39) and inhibitor (n = 30) were measured for a subset of individuals. RESULTS: Compared with clopidogrel-associated TTP cases (n = 35), ticlopidine-associated TTP cases (n = 93) were more likely to have received more than 2 weeks of drug (90% vs. 26%), to be severely thrombocytopenic (84% vs. 60%), and to have normal renal function (72% vs. 45%) (p < 0.01 for each). Compared with TTP patients with ADAMTS13 activity >15% (n = 13), TTP patients with severely deficient ADAMTS13 activity (n = 26) were more likely to have received ticlopidine (92.3% vs. 46.2%, p < 0.003). Among patients who developed TTP >2 weeks after thienopyridine, therapeutic plasma exchange (TPE) increased likelihood of survival (84% vs. 38%, p < 0.05). Among patients who developed TTP within 2 weeks of starting thienopyridines, survival was 77% with TPE and 78% without. CONCLUSIONS: Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatment. This drug toxicity appears to occur by 2 different mechanistic pathways, characterized primarily by time of onset before versus after 2 weeks of thienopyridine administration. If TTP occurs after 2 weeks of ticlopidine or clopidogrel therapy, therapeutic plasma exchange must be promptly instituted to enhance likelihood of survival. 相似文献
105.
106.
Bixio Riccardo Bertelle Davide Pistillo Francesca Pedrollo Elisa Carletto Antonio Rossini Maurizio Viapiana Ombretta 《Clinical rheumatology》2022,41(4):1247-1254
Clinical Rheumatology - Myasthenia gravis is an autoimmune disease affecting the neuromuscular junction, often associated with other autoimmune diseases, including rheumatoid arthritis. Patients... 相似文献
107.
Enrico Tincani Mark A Crowther Fabrizio Turrini Domenico Prisco 《Clinical Interventions in Aging》2007,2(2):237-246
Venous thromboembolism (VTE) is a common complication among hospitalized patients. Pharmacological thromboprophylaxis has emerged as the cornerstone for VTE prevention. As trials on thromboprophylaxis in medical patients have proven the efficacy of both low-molecular-weight heparins (LMWHs) and unfractionated heparin (UFH), all acutely medical ill patients should be considered for pharmacological thromboprophylaxis. Unlike in the surgical setting where the risk of associated VTE attributable to surgery is well recognized, and where widespread use of pharmacological thromboprophylaxis and early mobilization has resulted in significant reductions in the risk of VTE, appropriate VTE prophylaxis is under-used in medical patients. Many reasons for this under-use have been identified, including low perceived risk of VTE in medical patients, absence of optimal tools for risk assessment, heterogeneity of patients and their diseases, and fear of bleeding complications. A consistent group among hospitalized medical patients is composed of elderly patients with impaired renal function, a condition potentially associated with bleeding. How these patients should be managed is discussed in this review. Particular attention is devoted to LMWHs and fondaparinux and to measures to improve the safety and the efficacy of their use. 相似文献
108.
Buonaiuto D Rossi D Guidetti F Vivenza D Berra E Deambrogi C Ariatti C Franceschetti S Conconi A Ronco M Valente G Colombi S 《Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna》2002,17(1):54-59
Primary lymphomatous effusions are defined as lymphomas presenting in the serous body cavities in the absence of clinically identifiable tumor masses. Recently, a peculiar type of primary lymphomatous effusion associated with tumor clone infection by human herpesvirus type 8 (HHV-8) and preferentially arising in HIV-positive patients has been described and termed as primary effusion lymphoma (PEL). This report describes a case of PEL which has developed in a HIV-negative, 92-year-old man with longstanding Mediterranean Kaposi's sarcoma, a disease also associated with HHV-8 infection. The patient presented with pleural and ascitic effusions in the absence of solid masses within the lungs, mediastinum, thoracic wall or abdominal cavity. The effusions consisted of malignant lymphocytes with morphologic features bridging immunoblastic and anaplastic cells. Immunophenotypic studies revealed that the lymphoma population expressed an antigenic profile consistent with PEL, i.e. the absence of common B- and T-cell markers (non-B, non-T phenotype) coupled to CD138 positivity. Molecular analysis demonstrated infection of the tumor clone by HHV-8 as well as monoclonally rearranged immunoglobulin genes, consistent with a B-cell histogenesis of the lymphoma. In addition, this PEL case harbored PAX-5 gene mutations, which have been recently demonstrated as a key feature of the proto-oncogene hypermutation process involved in the pathogenesis of some lymphoma types. Following two courses of etoposide and prednisone, a partial remission was achieved. The patient died of liver failure 3 months after the diagnosis of PEL. Overall, this case report illustrates the need for an integrated diagnostic approach based on clinical features, morphology, immunophenotype, and molecular genetics to primary lymphomatous effusions. 相似文献
109.
Nencioni A Grünebach F Schmidt SM Müller MR Boy D Patrone F Ballestrero A Brossart P 《Critical reviews in oncology/hematology》2008,65(3):191-199
Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and thereby improve survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens to T-lymphocytes. Ex vivo generated DCs can be loaded with antigens and re-infused to the patients, or they can be used for ex vivo expansion of antitumor lymphocytes. Alternatively, methods exist to target antigens to DCs in vivo without need for ex vivo cell manipulations. The clinical studies have shown that DC administration to patients is safe and induces antigen-specific immunity. However, it seldom elicits objective clinical responses in patients with advanced-stage malignancies. Novel insights into DC and lymphocyte regulation are expected to lead to more effective vaccines in the near future. Meanwhile, efforts are directed at identifying the most appropriate clinical targets for active specific immunotherapies. Data suggests that vaccinations may indeed be beneficial when given in the adjuvant setting rather than to treat metastatic cancers. These issues are discussed here together with an overview of the DC-based antitumor immunotherapy studies. 相似文献
110.
Davide Porrelli Andrea Travan Gianluca Turco Matteo Crosera Massimiliano Borgogna Ivan Donati Sergio Paoletti Gianpiero Adami Eleonora Marsich 《Journal of tissue engineering and regenerative medicine》2018,12(2):e747-e759
Injectable bone fillers represent an attractive strategy for the treatment of bone defects. These injectable materials should be biocompatible, capable of supporting cell growth and possibly able to exert antibacterial effects. In this work, nanocomposite microbeads based on alginate, chitlac, hydroxyapatite and silver nanoparticles were prepared and characterized. The dried microbeads displayed a rapid swelling in contact with simulated body fluid and maintained their integrity for more than 30 days. The evaluation of silver leakage from the microbeads showed that the antibacterial metal is slowly released in saline solution, with less than 6% of silver released after 1 week. Antibacterial tests proved that the microbeads displayed bactericidal effects toward Staphylococcus aureus, Pseudomonas aeruginosa and Staphylococcus epidermidis, and were also able to damage pre‐formed bacterial biofilms. On the other hand, the microbeads did not exert any cytotoxic effect towards osteoblast‐like cells. After characterization of the microbeads bioactivity, a possible means to embed them in a fluid medium was explored in order to obtain an injectable paste. Upon suspension of the particles in alginate solution or alginate/hyaluronic acid mixtures, a homogenous and time‐stable paste was obtained. Mechanical tests enabled to quantify the extrusion forces from surgical syringes, pointing out the proper injectability of the material. This novel antibacterial bone filler appears as a promising material for the treatment of bone defects, in particular when possible infections could compromise the bone‐healing process. Copyright © 2016 John Wiley & Sons, Ltd. 相似文献